Silo Pharma Inc. (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for a patent application covering its lead asset, SPC-15. SPC-15 is an intranasal 5-HT4 receptor agonist being developed for the treatment of post-traumatic stress disorder (PTSD) and other stress-induced psychiatric disorders. This patent allowance marks a significant milestone in the company's global intellectual property strategy, as it expands protection for its lead candidate in a key international market.
The Canadian patent application is held under an exclusive license from Columbia University, through which Silo has the rights to further develop, manufacture, and commercialize SPC-15 worldwide. This allowance follows the recent grant of a corresponding European patent, indicating that the company's intellectual property is gaining traction across multiple jurisdictions. With these protections in place, Silo is positioning itself to capitalize on the growing demand for innovative treatments for PTSD, a condition that affects millions of individuals worldwide.
The significance of this development extends beyond mere patent protection. Silo intends to utilize the U.S. Food and Drug Administration's (FDA) streamlined 505(b)(2) regulatory pathway for SPC-15. This pathway allows for the submission of a new drug application that relies on data from existing studies, potentially shortening clinical timelines and reducing development costs. By leveraging this approach, Silo could accelerate the time-to-market for SPC-15, offering a new therapeutic option to patients who currently have limited effective treatments for PTSD.
The company's focus on stress-induced psychiatric disorders, chronic pain, and central nervous system diseases addresses underserved medical needs. Silo's portfolio includes SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. These programs are developed in collaboration with leading universities and laboratories, ensuring a robust scientific foundation.
The Canadian patent allowance also reinforces Silo's commitment to building a comprehensive intellectual property estate around its lead candidates. As the company advances SPC-15 through clinical development, this protection helps safeguard its commercial potential and provides a strong foundation for potential partnerships or licensing opportunities.
Investors and stakeholders view this development as a positive indicator of the company's progress in executing its strategic objectives. The global market for PTSD therapeutics is expected to grow significantly in the coming years, driven by increased awareness and diagnosis of the condition. Silo's early establishment of patent protection in key regions positions it well to capture a share of this market.
For more information about Silo Pharma and its pipeline, visit the company's website at silopharma.com. The latest news and updates relating to SILO are available in the company's newsroom at https://ibn.fm/SILO.
